Changing the way diseases are treated, Arrowhead pharmaceuticals uses innovative, scientific methods to discover, develop, and deliver therapies and solutions.

Check out the development of Arrowhead’s products to treat challenging cardiometabolic, pulmonary, neuromuscular, liver, and more types of diseases.

Dec 11, 2024 · The Investor Relations website contains information about Arrowhead Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.

Join Arrowhead and collaborate with our innovative experts. Let's push the boundaries of science and redefine the treatment of difficult diseases together.

Learn more about Arrowhead Pharmaceutical's foundation as a therapeutic discovery company, innovative use of RNAi, and ambitious pipeline for developing medicines.

Stay up to date on Arrowhead Pharmaceutical's latest news, stories, and events. Read about recent studies on potential treatments, healthcare conferences, and more!

Arrowhead is committed to bringing new investigational medicines to patients with serious diseases as quickly and efficiently as possible. The company has established an expanded access program (EAP) for some individuals living with FCS.

See Arrowhead's scientific and innovative discovery and development platform, producing effective new therapies that are cost effective and may have a lower risk.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity.

Dec 13, 2024 · Arrowhead Pharmaceuticals 2024 Second Quarter Results . Listen to webcast. Prepared Remarks 203.3 KB. Apr 6 - Apr 8, 2024 American College of Cardiology 73rd Annual Scientific Session & Expo . View Presentation 885.9 KB. Mar 13, 2024 8:00 AM EDT. Leerink Partners Global Biopharma Conference.